OptiBiotix Health PLC Director's dealing (3706U)

TIDMOPTI

RNS Number : 3706U

OptiBiotix Health PLC

12 July 2018

OptiBiotix Health plc

("OptiBiotix" or the "Company")

Director's dealing

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care was notified on 11 July 2018 that Neil Davidson, Non-Executive Chairman of the Company, acquired 210,000 ordinary shares in the Company on 11 July 2018, representing 0.25% of the Company's issued share capital, at a price of 71 pence per share.

Previously to this notification, Mr Davidson held 165,000 ordinary shares in the Company. Therefore Neil Davidson's total shareholding represents 0.44% of the Company's issued share capital.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 and the person who arranged for release of this announcement on behalf of the Company was Stephen O'Hara, Chief Executive.

For further information, please contact:

 
 OptiBiotix Health plc                                                www.optibiotix.com 
 Stephen O'Hara, Chief Executive                              Contact via Walbrook below 
 
 Cairn Financial Advisers LLP                                         Tel: [phone] 
 Liam Murray / Jo Turner 
 
 finnCap (Broker)                                                     Tel: [phone] 
 Adrian Hargrave / Scott Mathieson / Kate Bannatyne 
  (Corporate Finance) 
 Abigail Wayne (Corporate Broking) 
 
 Walbrook PR Ltd                         Tel: [phone] or [e-mail] 
 Anna Dunphy                                                          Mob: [phone] 
 
 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen(R) and OptiBiotic(R) platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits.

 
 Notification of a Transaction pursuant to Article 19(1) of Regulation 
  (EU) No. 596/2014 
 1       Details of the person discharging managerial responsibilities/person 
          closely associated 
        ------------------------------------------------------------------------------- 
 a.      Name                                     Neil Davidson 
        ---------------------------------------  -------------------------------------- 
 2       Reason for notification 
        ---------------------------------------  -------------------------------------- 
 a.      Position/Status                          Non-Executive Chairman 
        ---------------------------------------  -------------------------------------- 
 b.      Initial notification/                    Initial Notification 
          Amendment 
        ---------------------------------------  -------------------------------------- 
 3       Details of the issuer, emission allowance market participant, 
          auction platform, auctioneer or auction monitor 
        ------------------------------------------------------------------------------- 
 a.      Name                                     OptiBiotix Health plc 
        ---------------------------------------  -------------------------------------- 
 b.      LEI                                      213800UKYQFT941QHS14 
        ---------------------------------------  -------------------------------------- 
 4       Details of the transaction(s): section to be repeated for 
          (i) each type of instrument; (ii) each type of transaction; 
          (iii) each date; and (iv) each place where transactions have 
          been conducted 
        ------------------------------------------------------------------------------- 
 a.      Description of 
          the financial                            Ordinary shares 
          instrument, type 
          of instrument 
 
          Identification                           ISIN: GB00BP0RTP38 
          Code 
        ---------------------------------------  -------------------------------------- 
 b.      Nature of the                             Purchase of ordinary shares 
          transaction 
        ---------------------------------------  -------------------------------------- 
 
 c.      Price(s) and volume(s)                    Price(s) per         Volume(s) 
                                                    share 
        ---------------------------------------   ------------------- 
 
      71 pence                                                            210,000 
   ------------------------------------------------------------------  ------------- 
 
 d.      Aggregated information 
 
          - Aggregated Volume                       210,000 
 
          - Price                                   71 pence 
        ---------------------------------------  -------------------------------------- 
 e.      Date of the transaction                  11 July 2018 
        ---------------------------------------  -------------------------------------- 
 f.      Place of the transaction                 AIM 
        ---------------------------------------  -------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHQFLFFVDFBBBD

(END) Dow Jones Newswires

July 12, 2018 02:00 ET (06:00 GMT)